On 25 May 2018, orphan designation (EU/3/18/2017) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (also known as JCAR017) for the treatment of follicular lymphoma.
The sponsorship was transferred to Celgene Europe B.V., the Netherlands, in February 2019.
The sponsorship was transferred to Bristol-Myers Squibb Pharma EEIG, Ireland in January 2021.
This medicine is now known as lisocabtagene maraleucel.
Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (lisocabtagene maraleucel)
Treatment of follicular lymphoma
|Date of designation||
|Orphan designation status||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.